The once-weekly insulin icodec, now approved and launched in India for adults living with diabetes, could potentially reduce ...

Introducing continuous glucose monitoring in primary care optimizes diabetes management in underserved populations.

India has launched Awiqli, the world's first once-weekly insulin, offering fewer injections and potentially improving ...

The 170-acre northeast-side Indianapolis campus is composed of 21 buildings and serves as one of the company’s two global hubs.

The Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) program is an innovative, patient-centered system of care developed by the University Hospitals Harrington Heart ...

A review highlights hearing loss as a hidden complication of type 2 diabetes. It notes that roughly 1 in 4 experience hearing ...

Many adults with diabetes have uncontrolled or previously undiagnosed high blood pressure during their routine visits to ...

Teplizumab is an immunotherapy drug designed to modify the immune system's response. Instead of simply treating symptoms, it works on the underlying cause of Type 1 diabetes. The medicine helps stop ...

Building a system that can recognise risk, guide families, and protect children before Type 1 Diabetes becomes clinical ...

India becomes seventh market for Awiqli as drugmaker targets delays in insulin initiation among people with diabetes.

More frequent routine primary care visits for certain higher-risk commercially insured adults are associated with lower net population-level health care costs. Objective: To evaluate the relationship ...